[HTML][HTML] A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia
F You, Y Wang, L Jiang, X Zhu, D Chen… - American journal of …, 2019 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia
F You, Y Wang, L Jiang, X Zhu… - … journal of cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia.
F You, Y Wang, L Jiang, X Zhu, D Chen… - American Journal of …, 2019 - europepmc.org
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
[PDF][PDF] A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia
F You, Y Wang, L Jiang, X Zhu, D Chen, L Yuan, G An… - e-century.us
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …